After-hours PTS information for Immuno-Biological Laboratories Co.,Ltd. has been published, along with reports that sales and profits rose substantially in the first quarter of the fiscal year ending March 2027. The company also announced the consolidation of manufacturing sites and the discontinuation of some testing services.
This Yahoo! Finance article summarizes the first-quarter results for the fiscal year ending March 2027 of Immuno-Biological Laboratories Co.,Ltd., along with the publication of after-hours PTS information. According to the summary of the earnings release, net sales rose 35.2% year on year to ¥286 million, operating profit increased 116.5% to ¥117.77 million, and net profit rose 64.5% to ¥12.56 million, while the full-year forecast was left unchanged.
Meanwhile, the company announced on the same day the consolidation of manufacturing sites and the discontinuation of some testing services as part of a review of its business strategy, with the restructuring of its current earnings structure cited as a factor. After closing at ¥1,210 on 25 September following movements around 13 September, the share price fell back on 28 September from the previous day to ¥1,167.
The figures for after-hours PTS price-movement indicators and changes versus the TSE closing price remained unconfirmed in the after-hours trading information, while figures for the trading price, volume and trading value remained in fields showing actual trading conditions. The summary of the earnings release and the key points for monitoring future performance cite factors including increased sales of diagnostic reagents and an improved mix of higher-margin products.